L. Maurissen

发表

A positive family history for premature cardiovascular disease identifies patients prone to recurrent arterial thrombotic events

A. Kroon, C. Stehouwer, I. Ferreira, 2012, European journal of preventive cardiology.

Protein S is a cofactor for tissue factor pathway inhibitor.

J. Rosing, T. Hackeng, G. Tans, 2008, Thrombosis research.

Thrombin generation‐based assays to measure the activity of the TFPI–protein S pathway in plasma from normal and protein S‐deficient individuals

J. Rosing, P. Simioni, T. Hackeng, 2010, Journal of thrombosis and haemostasis : JTH.

DUSP3 Phosphatase Deficiency or Inhibition Limit Platelet Activation and Arterial Thrombosis Running title: Musumeci et al.; DUSP3, a new player in arterial thrombosis

T. Mustelin, T. Chung, E. Théâtre, 2014 .

Regulation of TFPI function by protein S

J. Rosing, T. Hackeng, E. Castoldi, 2009, Journal of thrombosis and haemostasis : JTH.

Re-evaluation of the role of the protein S-C4b binding protein complex in activated protein C-catalyzed factor Va-inactivation.

B. Dahlbäck, G. Nicolaes, J. Rosing, 2008, Blood.

Dual-Specificity Phosphatase 3 Deficiency or Inhibition Limits Platelet Activation and Arterial Thrombosis

T. Mustelin, T. Chung, E. Théâtre, 2014, Circulation.

activated protein C-catalyzed factor Va-inactivation Re-evaluation of the role of the protein S-C4b binding protein complex in

B. Dahlbäck, G. Nicolaes, J. Rosing, 2013 .

Increased tissue factor pathway inhibitor activity is associated with myocardial infarction in young women: results from the RATIO study

A. Algra, F. Rosendaal, H. ten Cate, 2011, Journal of thrombosis and haemostasis : JTH.

DUSP 3 Phosphatase Deficiency or Inhibition Limit Platelet Activation and Arterial Thrombosis

T. Mustelin, T. Chung, E. Théâtre, 2014 .

Background—A limitation of current antiplatelet therapies is their inability to separate thrombotic events from bleeding occurrences. A better understanding of the molecular mechanisms leading to platelet activation is important for the development of improved therapies. Recently, protein tyrosine p

T. Mustelin, T. Chung, E. Théâtre, 2015 .

Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from families with mixed type I/III protein S deficiency

J. Rosing, P. Simioni, D. Tormene, 2010, Haematologica.

Similar hypercoagulable state and thrombosis risk in type I and type III protein S-deficient individuals from mixed type I/III families.

J. Rosing, P. Simioni, D. Tormene, 2010, Haematologica.